The treatment landscape for relapsed, refractory multiple myeloma has been constantly evolving with new treatments and trials keeping everyone on their toes. Following the Amgen Multiple Myeloma Webinar Series we speak to Dr Jesús San Miguel and Dr Paula Rodriguez from the University of Pamplona, Spain about where carfilzomib fits in the current treatment paradigm. ...
Podcast: Where does carfilzomib fit in the R/R multiple myeloma setting?
4 Dec 2020
Sponsored by Amgen Australia Pty Ltd